NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
The Innopack confex is a perfect platform for exhibitors to demonstrate their latest developments in the fields of pharmaceutical packaging, labelling, drug delivery device design and engineering.
The drug will be manufactured at the group’s topical facility at Ahmedabad
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The companies will jointly identify and develop molecular glue degraders up to a clinical candidate stage.
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
AstraZeneca also played a critical role in the global response to COVID-19.
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Subscribe To Our Newsletter & Stay Updated